Gunderson Dettmer represented client Kelonia Therapeutics, a biotech company focused on revolutionizing in vivo gene delivery, in its $50 million Series A financing round with participation from Alta Partners, Horizons Ventures, and Venrock. The company focuses on building a pipeline of genetic medicines for a wide range of diseases. The new capital will be used to develop genetic medicines starting with an “off-the-shelf” chimeric antigen receptor (CAR) to treat hematologic cancer, advance other programs for oncology and non-oncology indications, and further expand its gene delivery platform and capabilities.

In the announcement of the transaction, President and Chief Scientific Officer of Kelonia Kevin Friedman, Ph.D. said, “At Kelonia, we believe we have found an in vivo gene delivery solution that is safe, effective, and manufacturable for broad therapeutic application. With our Series A funding and key strategic collaborations, we will advance our lead product candidate toward clinical studies and further optimize our technology to explore treating diseases never thought possible with genetic medicines.”

The Gunderson deal team was led by Tim Ehrlich and included Aliya Sanders, Christopher Warren, and Jake Lebowitz.

Companies:
Kelonia Therapeutics 
Alta Partners
Horizons Ventures
Venrock